LillyDirect Zepbound self-pay prices confirmed at $299 to $449 with a 45-day refill condition

As of September 5, 2026, LillyDirect self-pay prices for Zepbound, the brand name for tirzepatide, are $299 a month for 2.5 mg, $399 for 5 mg and $449 for 7.5 mg through 15 mg — provided the patient refills within 45 days of the previous fill ^[1][2]. A pricing review published that day confirmed the ladder and corrected earlier figures, including flat $349 and $499 prices, that do not appear in Lilly's 2026 terms ^[1].

Miss the 45-day window and the price changes sharply. The regular self-pay price is $499 for 7.5 mg and $699 for 10 mg, 12.5 mg and 15 mg ^[1][2]. At those maintenance doses, the refill rule is the difference between $449 and $699 a month, or $250 a month ^[1][2]. The same prices apply to the single-dose vials and to the Zepbound KwikPen, the multi-dose pen that launched February 23, 2026; each KwikPen holds 10 mg in 2.4 mL and delivers four weekly doses, and the self-pay KwikPen program allows up to 11 fills per calendar year ^[1].

The September review also withdrew several figures that had circulated earlier in coverage: a Tier 2 increase to $650, a $469 per-fill cap, flat $349 and $499 LillyDirect prices, a $1,499 three-month bundle and free 2-day shipping. The review states that none of those appear in Lilly's 2026 terms, and it removed 2027 predictions that had been built on the premise that prices rose in 2026 ^[1].

Other Zepbound routes carry their own numbers. Commercially insured patients whose plan covers the drug pay as little as $25 per fill, with the savings card paying up to $100 per 1-month fill and $1,300 per calendar year across 13 fills; the card expires December 31, 2026 ^[1]. Commercially insured patients whose plan does not cover Zepbound pay $499 for a 1-month single-dose pen fill, or $299 for the 2.5 mg KwikPen, down from $650 under the 2025 card ^[1]. Medicare enrollees remain excluded from the savings card, but the Medicare GLP-1 Bridge caps the Zepbound KwikPen at $50 a month with prior authorization from July 1, 2026 through December 31, 2027 ^[1][2]. Retail cash pricing with no program at all runs about $1,086 a month ^[2].

One price tracker lists both the 2.5 mg and 5 mg doses at $299 in one section, while its own dose-by-dose figures put 5 mg at $399; Lilly's published terms and the other review give $399 at 5 mg ^[1][2]. Compounded tirzepatide, which the FDA has not approved and which is not Zepbound, is tracked separately: a price index reported a median of $299 per 28 days at the 2.5 mg weekly dose across 14 providers, with a range of $149 to $470, as of September 3, 2026 ^[1]. A separate tracker lists a floor of $149 a month at one provider and $278 flat at another ^[2].

Why it matters for patients

For people paying cash, the refill deadline is part of the price, not a footnote. At 10 mg and above, filling on day 46 instead of day 44 costs $250 more for that month, and the gap is $3,000 over a year at that dose ^[1][2]. At 7.5 mg, the gap is $50 a month. The lower tier — $299 at 2.5 mg — is the starting dose, so patients who stay on it pay less than patients who titrate up to maintenance doses ^[1][2].

Which path is cheapest depends on coverage. The savings card at $25 a month remains far below any cash option, but it requires commercial insurance that covers Zepbound ^[1]. For patients whose plan does not cover the drug, the card price of $499 for a 1-month pen fill now sits close to the LillyDirect range of $299 to $449, while the Medicare Bridge at $50 undercuts both for eligible Part D enrollees who can get the KwikPen ^[1][2]. Whether an individual qualifies for the Bridge depends on prior authorization and CMS clinical criteria; the reviews do not list those criteria in full ^[1][2].

What happens next

The 2026 Zepbound savings card expires December 31, 2026, and LillyDirect program pricing also ends December 31, 2026 ^[1][2]. Lilly publishes new terms each January, and the Medicare GLP-1 Bridge runs through December 31, 2027 ^[1]. No 2027 self-pay prices for Zepbound have been disclosed ^[1][2].